ALK and non-small cell lung carcinoma: Results showed that alectinib did not increase the overall survival compared with crizotinib. However, alectinib remains the standard of care for ALK-positive non-small-cell lung cancer; this has been shown to delay the progression of metastasis mainly to the CNS regions